European regulators cast doubt on Biogen Alzheimer’s treatment
EMA vote deals a setback to controversial $56,000-a-year treatment
Alzheimer’s drug hopes see Biogen shares surge 27%
Pharma group resurrects pipeline therapy it abandoned as ineffective earlier this year
Drug that can halt Alzheimer’s may be on the horizon
Early-stage clinical trial involving aducanumab has yielded promising results
YOU MAY ALSO LIKE...
Crosswords & Puzzles
Crosswords & puzzles to keep you challenged and entertained
Election 2024
Full general election coverage including analysis and results for all 43 constituencies
Common Ground
How does a post-Brexit world shape the identity and relationship of these islands
Family NoticesOpens in new window
Weddings, Births, Deaths and other family notices